Xenon Pharmaceuticals Inc.

XENE

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001582313

SEC filings (opens in a new tab)

In the last 90 days, Xenon Pharmaceuticals Inc. insiders filed 2 open-market purchases and 2 sales; 315 institutions reported holding it in 13F filings for Q2 2026, worth $6.10B in total; Duquesne Family Office is the only superinvestor holding it.

Q1 2024 vs. Q4 2023

How the institutions holding Xenon Pharmaceuticals Inc. changed between Q4 2023 and Q1 2024.

All holders in Q1 2024 All holders in Q4 2023

13F holders of XENE: Q4 2023 compared with Q1 2024
Measure	Q4 2023	Of which not filed for Q1 2024	Q1 2024	Change
Holders	204	1	220	+17
Shares	72.1M	215.5K	73.5M	+1.65M (+2.3%)
Value	$3.32B	$9.93M	$3.16B	−$145.6M (−4.4%)

1 institution that held it in Q4 2023 haven't filed for Q1 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (36)

Institutions that held Xenon Pharmaceuticals Inc. at the end of Q1 2024 but not at the end of Q4 2023.

Institutions new to XENE in Q1 2024
Institution	Shares	Value	% of portfolio
BNP PARIBAS ASSET MANAGEMENT Holding S.A.	416,736	$17.9M	0.05%
Artal Group S.A.	253,387	$10.9M	0.28%
Alyeska Investment Group, L.P.	238,843	$10.3M	0.06%
Ikarian Capital, LLC	107,187	$4.61M	1.26%
Twinbeech Capital LP	98,042	$4.22M	0.09%
Trexquant Investment LP	46,874	$2.02M	0.04%
Qube Research & Technologies Ltd	45,286	$1.95M	0.00%
Artia Global Partners LP	40,000	$1.72M	0.42%
Engineers Gate Manager LP	26,513	$1.14M	0.03%
Gsa Capital Partners LLP	21,614	$930.0K	0.07%
Y-Intercept (Hong Kong) Ltd	18,305	$788.0K	0.06%
Eisler Capital (US) LLC	16,654	$717.0K	0.24%
Gilder Gagnon Howe & Co LLC	15,092	$649.7K	0.01%
Bayesian Capital Management, LP	9,700	$417.6K	0.04%
Entropy Technologies, LP	9,649	$415.4K	0.04%
Man Group plc	6,900	$297.0K	0.00%
Virtu Financial LLC	6,661	$287.0K	0.02%
Cubist Systematic Strategies, LLC	5,105	$219.8K	0.00%
HighMark Wealth Management LLC	5,000	$215.3K	0.13%
NEOS Investment Management LLC	4,972	$214.0K	0.01%
Corton Capital Inc.	4,864	$209.4K	0.08%
EntryPoint Capital, LLC	4,541	$195.5K	0.18%
Harbor Capital Advisors, Inc.	3,225	$139.0K	0.02%
Allianz SE	1,200	$51.7K	0.00%
Bank of Montreal	909	$39.3K	0.00%
Nelson, Van Denburg & Campbell Wealth Management Group, LLC	302	$13.0K	0.00%
State of Wyoming	300	$12.9K	0.00%
Mitsubishi UFJ Kokusai Asset Management Co., Ltd.	276	$11.9K	0.00%
Bell Investment Advisors, Inc	30	$1.29K	0.00%
Rhumbline Advisers	29	$1.25K	0.00%
Park Place Capital Corp	18	$775	0.00%
Continuum Advisory, LLC	15	$637	0.00%
Allworth Financial LP	12	$517	0.00%
C M Bidwell & Associates Ltd	9	$387	0.00%
Lindbrook Capital, LLC	3	$129	0.00%
17 Capital Partners, LLC	2,840	–	–

Sold out (19)

Institutions that held Xenon Pharmaceuticals Inc. at the end of Q4 2023 and filed for Q1 2024 without it.

Institutions that sold out of XENE in Q1 2024
Institution	Shares, Q4 2023	Value, Q4 2023
BVF Inc	890,072	$41.0M
Woodline Partners LP	196,453	$9.05M
Logos Global Management LP	150,000	$6.91M
Soleus Capital Management, L.P.	58,000	$2.67M
Lighthouse Investment Partners, LLC	27,775	$1.28M
Campbell & CO Investment Adviser LLC	17,973	$827.8K
Ghisallo Capital Management LLC	10,000	$460.6K
Squarepoint Ops LLC	8,253	$380.1K
Omers Administration Corp	7,700	$354.7K
Nebula Research & Development LLC	7,281	$335.4K
Natixis	7,000	$322.4K
Fox Run Management, L.L.C.	6,595	$303.8K
Walleye Capital LLC	5,054	$232.8K
Weiss Multi-Strategy Advisers LLC	5,000	$230.0K
Lynwood Capital Management Inc.	2,500	$115.2K
Cambridge Trust Co	300	$13.8K
Headlands Technologies LLC	23	$1.06K
Crewe Advisors LLC	4	$185
AdvisorNet Financial, Inc	2	$92

Not filed for Q1 2024 yet (1)

Institutions that held Xenon Pharmaceuticals Inc. at the end of Q4 2023 and haven't filed a 13F for Q1 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding XENE in Q4 2023 that haven't filed for Q1 2024
Institution	Shares, Q4 2023	Value, Q4 2023
Putnam Investments LLC	215,545	$9.93M